Search
Allogene Therapeutics Inc
ALLOAdd to Watchlist
1.670USD
0.0000.00%
Close 09-24 16:00（ET）
576.40MMarket Cap
LossP/E TTM
After-hours 19:34 (ET)1.720USD+0.050+2.99%
After-hours 19:34 (ET)TradingKey Chart
Intraday
1m
30m
1h
D
W
M
D
Today
0.00%
5 Days
-3.47%
1 Month
-17.73%
6 Months
-24.43%
Year to Date
+21.90%
1 Year
+35.77%
Key Figures
1.670Open
1.740High
903.56KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.26%Turnover Ratio
1.670Prev. Close
1.600Low
1.50MTurnover
LossP/E Static
1.32P/B
0.00%Div Yield TTM
-38.45%ROA
4.46052wk High
52.03Volume Ratio
-257.59MNet Profit
345.15MShares
-0.7651EPS TTM
0.47Beta
-52.32%ROE
1.04052wk Low
8.38%Amplitude
100.00%Gross Margin
576.40MMarket Cap
3.00Reward/Risk
5.35%Risk Rate
Allogene Therapeutics Inc's Score
-0.05vs previous score
Forecast8.50
Financial Health6.88
Technical4.42
Valuation Dimensions6.43
Institutional Confidence3.00
Risk Assessment5.14
Media Coverage
Coverage Level
Very Low
Very High
Positive
Analyst Rating
Allogene Therapeutics Inc Technical Analysis
Technical Indicators
Strong sell
Summary
Sell
Moving Average
Strong sell
Allogene Therapeutics Inc Latest Earnings Call Transcripts
Allogene Therapeutics (ALLO) Q2 2026 Earnings Call: ALPHA3 Site Expansion and Pipeline Updates
Allogene Therapeutics’ Q2 2026 earnings call covers ALPHA3’s 100-site target, FDA designations, ALLO-316 results and ALLO-329’s Q4 update.
Financial Indicators
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
Earnings
Next reporting date
--
Reporting Period
2026Q2
Earnings / Forecast
-0.13/-0.17
Revenue / Forecast
4.64M/2.22K
Allogene Therapeutics Inc Profile
SectorBiotechnology & Medical Research
Ticker SymbolALLO
Number of employees226
CountryUnited States of America
Ownership
| Shareholders | Proportion |
|---|---|
| Pfizer Inc | 6.39% |
| TPG Capital, L.P. | 5.42% |
| Frazier Life Sciences Management, L.P. | 4.70% |
| Citadel Advisors LLC | 3.51% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 16.18% |
| Private Equity | 12.41% |
| Hedge Fund | 8.61% |
| Investment Advisor/Hedge Fund | 7.80% |
Related Instruments
+2.68%
+0.56%
+0.02%
-0.07%
+0.60%
+0.75%
-0.01%
-1.11%
+1.18%
+0.82%
+1.17%
+0.57%
-1.27%
-0.12%
-1.73%
-0.72%
+6.98%
+1.73%
-1.17%
+0.61%
FAQs
What is the current price of Allogene Therapeutics Inc (ALLO)?
The current price of Allogene Therapeutics Inc (ALLO) is 1.67.
What is the symbol of Allogene Therapeutics Inc?
The ticker symbol of Allogene Therapeutics Inc is ALLO.
What is the 52-week high of Allogene Therapeutics Inc?
The 52-week high of Allogene Therapeutics Inc is 4.46.
What is the 52-week low of Allogene Therapeutics Inc?
The 52-week low of Allogene Therapeutics Inc is 1.04.
What is the market capitalization of Allogene Therapeutics Inc?
The market capitalization of Allogene Therapeutics Inc is 576.40M.
Is Allogene Therapeutics Inc (ALLO) currently rated as Buy, Hold, or Sell?
According to analysts, Allogene Therapeutics Inc (ALLO) has an overall rating of Buy, with a price target of 9.00.
What is the Earnings Per Share (EPS TTM) of Allogene Therapeutics Inc (ALLO)?
The Earnings Per Share (EPS TTM) of Allogene Therapeutics Inc (ALLO) is -0.77.